Glenbeigh is pleased to announce the publication of a study conducted by Dr. Carolanne Semancik, Manager of Quality, Risk Management, and Training. Dr. Semancik conducted an in-depth examination of records over an eight-month period, from July 2023 to February 2024. The study provides early evidence supporting the previously theorized connection between xylazine exposure and wound development.
The pain associated with xylazine-related wounds can lead to an unfortunate cycle in which individuals inject xylazine at the wound site to temporarily alleviate pain. This practice may cause further wound complications.
The study identified a statistical association between xylazine exposure and an increased prevalence of wounds. Individuals exposed to xylazine were found to be 2.4 times more likely to develop wounds compared to those exposed to fentanyl but not xylazine. This research emphasizes the importance of equipping professionals who work with individuals with substance use disorders to recognize and address the potential for an increased occurrence of wounds associated with xylazine exposure.
Further research is needed to investigate the mechanisms through which xylazine affects soft tissue, potentially making individuals more susceptible to wound development.
The publication of this study in the prestigious Journal of Addiction Medicine is a significant achievement, highlighting Dr. Semancik's dedication to advancing our understanding of substance use disorders and their associated complications. Glenbeigh congratulates Dr. Semancik on this well-deserved recognition and her invaluable contributions to the field of addiction medicine.
Read the entire study in the Journal of Addiction Medicine.